TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
Retinal Vein OcclusionMacula Edema
Interventions
DRUG

TLC399 (ProDex)

2-vial system: TLC399-DSP and TLC399-Lipid

Trial Locations (20)

14620

Retina Associates of Western New York, PC, Rochester

22903

University of Virginia, Charlottesville

28210

Charlotte Eye Ear Nose & Throat Assoc, PA, Charlotte

30060

Georgia Retina, P.C, Marietta

33126

Retina Macula Specialists of Miami, Miami

44915

The Cleveland Clinic, Cleveland

77030

Retina Consultants of Houston, Houston

77384

Retina Consultants of Houston,The Woodlands, The Woodlands

78240

Medical Center Ophthalmology Associates, San Antonio

Retinal Consultants of San Antonio, San Antonio

78705

Retina Research Center, Austin

79606

Retina Research Institute of Texas, Abilene

80401

Colorado Retina Associates, Golden

85014

Retinal Research Institute, Phoenix

89149

Retina Consultants of Nevada, Las Vegas

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

91007

Retina Institute of California, Arcadia

92260

Retina Institute of California, Palm Desert

09320

Retina Group of New England, New London

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY